注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

【转载】The Lancet-Oncology(May 16 2016)  

2016-05-17 16:53:20|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Logo
Weekly Update
May 16, 2016
Weekly Features:
PR J Bernard/CNRI/Science Photo Library
Research | An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI)
The International CLL-IPI Working Group propose a new international prognostic index for chronic lymphocytic leukaemia.
Read this Article →
Podcast
Podcast | Ethical issues in paediatric oncology trials
In this month's podcast, Jean-Claude Dupont and Fran?ois Doz discuss ethical issues in paediatric oncology clinical trials.
Listen to this podcast →
Online First:
NEWS
Australia tax increases to price cigarettes out of reach
Continuing with its multifaceted strategy to reduce tobacco use, Australia has announced in its latest annual budget that it will increase tax on cigarettes by 12·5% each year for the next 4 years.
Read this Report →
PM Motta & S Makabe/Science Photo Library
NEWS
New risk loci for endometrial cancer identified
New research has identified five gene regions associated with a heightened risk of endometrial cancer.
Read this Report →
Steve Gschmeissner/Science Photo Library
COMMENT
Venetoclax: a new weapon to treat high-risk CLL
Davide Rossi comments on Stephan Stilgenbauer and colleagues' study assessing the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia.
Read this Comment →
ARTICLES
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
The aim of this phase 2, single-arm, multicentre study was to assess the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia.
Read this Article →
Zephyr/Science Photo Library
COMMENT
Pathological complete remission and long-term outcome—what do we know in 2016?
Michael Gnant, Guenther Steger, and Rupert Bartsch comment on Luca Gianni and colleagues' 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere).
Read this Comment →
ARTICLES
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. This paper reports 5-year progression-free survival, disease-free survival, and safety.
Read this Article →
PR J Bernard/CNRI/Science Photo Library
COMMENT
Analysis of prognosis in chronic lymphocytic leukaemia: collaboration makes the difference
Marinus van Oersemail comments on the International CLL-IPI Working Group's proposal for a new international prognostic index for chronic lymphocytic leukaemia (CLL-IPI).
Read this Comment →
ARTICLES
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
The International CLL-IPI Working Group propose a new international prognostic index for chronic lymphocytic leukaemia.
Read this Article →
Announcements:
Alerts
Stay Connected
You are receiving The Lancet Oncology Weekly Update as an extension to the Table of Contents alert service to which you are subscribed. 

If you would prefer not to receive these weekly updates, but wish to continue receiving the monthly Table of Contents alert, please click here:
Unsubscribe from Weekly Updates →

For all the very latest news, comment, and research follow The Lancet Oncology on Twitter.
Follow us →
Chicago skyline aerial view at dusk - marchello74
Attending ASCO in Chicago this June?
Visit us at the Elsevier booth #4031 to meet Isabel Lokody, Senior Editor ofThe Lancet Oncology and Lan-Lan Smith, Editor of The Lancet Haematology to discuss how to submit your research.

We’ll also be distributing free copies of The Lancet Oncology and special Commissions which highlight some of the key challenges and solutions in tackling the global cancer epidemic.
See you there! →
This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. 

Copyright ? 2016 Elsevier Limited. All rights reserved. THE LANCET ? is a registered trademark of RELX Intellectual Properties SA, used under license. 

To unsubscribe from The Lancet Oncology Weekly Updates, but continue receiving the monthly Table of Contents alert, please click here →

To unsubscribe from all Table of Contents alerts, please edit your mailing preferences by logging in to your TheLancet.com account: 

Update mailing preferences
  评论这张
 
阅读(9)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017